Human Liver Aldehyde Oxidase: Inhibition by 239 Drugs

Journal of Clinical Pharmacology

Volumn 44, Issue 1, 2004, Pages 7-19

  Obach, R Scott ^a   Huynh, Phuong ^b   Allen, Mary C ^b   Beedham, Christine ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

Aldehyde oxidase; Aldehyde oxidase inhibition; Drug interactions; Drug metabolism

Indexed keywords

1 PHTHALAZINONE; ACETYLSALICYLIC ACID; ACICLOVIR; ALDEHYDE OXIDASE; AMODIAQUINE; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOBENZAPRINE; DOMPERIDONE; ESTRADIOL; ETHINYLESTRADIOL; KETOCONAZOLE; KETONE; LIVER ENZYME; LORATADINE; MAPROTILINE; MEPACRINE; ONDANSETRON; PARACETAMOL; PHENOTHIAZINE DERIVATIVE; PHTHALAZINE DERIVATIVE; PROPAFENONE; RALOXIFENE; SALMETEROL; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TACRINE; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; DRUG CLASSIFICATION; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; LIVER CYTOSOL; MASS SPECTROMETRY; SENSITIVITY AND SPECIFICITY;

ALDEHYDE OXIDASE; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOSOL; DRUG INTERACTIONS; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0347364803     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003260336     Document Type: Article

References (29)

1. Greenblatt DJ, Von Moltke LL: Drug-drug interactions: clinical perspective, in: Rodrigues AD (ed.), Drug-Drug Interactions. New York: Marcel Dekker, 2002;565-584.
2. Clarke SE, Jones BC: Human cytochromes P450 and their role in metabolism-based drug-drug interactions, in: Rodrigues AD (ed.), Drug-Drug Interactions. New York: Marcel Dekker, 2002;55-88.
3. Beedham C: Molybdenum hydroxylases, in: Ioannides C (ed.), Enzyme Systems that Metabolise Drugs and Other Xenobiotics. New York: John Wiley, 2002;147-187.
4. Rashidi MR, Smith JA, Clarke SE, Beedham C: In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab Disp 1997;25:805-813.
5. Lake BG, Ball SE, Kao J, Renwick AB, Price RJ, Scatina JA: Metabolism of zaleplon by human liver: evidence for involvement of aldehyde oxidase. Xenobiotica 2002;32:835-847.
6. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, et al: Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver slices. Xenobiotica 2002;32:849-862.
7. Kawashima K, Hosoi K, Naruke T, Shiba T, Kitamura M, Watabe T: Aldehyde oxidase dependent marked species difference in hepatic metabolism of the sedative hypnotic zaleplon, between monkeys and rats. Drug Metab Disp 1999;27:422-428.
8. Sugihara K, Kitamura S, Tatsumi K: Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab Dispos 1996;24:199-202.
9. Kamel A, Prakash C, Obach S: Determination of the enzymes involved in the reductive cleavage of ziprasidone to dihydroziprasidone and the formation of S-methyldihydroziprasidone using human in vitro systems and electrospray ionisation tandem mass spectrometry (ESI/MS/MS). Paper presented at the 50th ASMS Conference, Orlando, FL, May 2002.
10. 1′(5′)-iminium ion. Biochem Biophys Res Comm 1979;91:991-999.
11. Hibberd AR, Gorrod JW: Enzymology of the metabolic pathway from nicotine to cotinine, in vitro. Eur J Drug Metab Pharmacokinet 1983;8:151-162.
12. Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P: Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 1998;56:15-23.
13. Ruenitz PC, Bai X: Acidic metabolites of tamoxifen: aspects of formation and fate in the female rat. Drug Metab Dispos 1995;23:993-998.
14. Wright RM, Weigel LK, Varella-Garcia M, Vaitaitis G, Repine JE: Molecular cloning, refined chromosomal mapping, and structural analysis of the human gene encoding aldehyde oxidase (AOX1), a candidate for the ALS2 gene. Redox Rep 1997;3:135-144.
15. Garattini E, Mendel R, Romao MJ, Wright R, Terao M: Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 2003;372:15-32.
16. Johns DG: Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 1967;46:1492-1505.
17. Rashidi MR, Smith JA, Clarke SE, Beedham C: Inhibition of human and guinea pig liver aldehyde oxidases in vitro. J Pharm Pharmacol 1995;47:1090.
18. Rajagapolan KV, Fridovich I, Handler P: Hepatic aldehyde oxidase: I. Purification and properties. J Biol Chem 1962;237:922-928.
19. Robertson GC, Gamage RS: Methadone, a potent inhibitor of rat liver aldehyde oxidase. Biochem Pharmacol 1994;47:584-587.
20. Schofield PC, Robertson IGC, Paxton JW: Inter-species variation in the metabolism and inhibition of N-[(2′ -dimethylaminoethyl]acridine-4-carboxamide (DACA) by aldehyde oxidase. Biochem Pharmacol 2000;59:161-165.
21. Beedham C, Critchley DJP, Rance DJ: Substrate specificity of human liver aldehyde oxidase toward substituted quinazolines and phthalazines: a comparison with hepatic enzyme from guinea pig, rabbit, and baboon. Arch Biochem Biophys 1995;319:481-490.
22. Beedham C, Bruce SE, Critchley DJ, Rance DJ: 1-Substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases. Biochem Pharmacol 1990;39:1213-1221.
23. Johnson C, Stubley-Beedham C, Stell JGP: Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem Pharmacol 1985;34:4251-4256.
24. Clarke SE, Harrell AW, Chenery RJ: Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995;23:251-254.
25. Stubley C, Stell JGP: Investigation of the substrate-binding site of aldehyde oxidase. J Pharm Pharmacol 1980;32(Suppl.):51P.
26. Critchley DJP, Rance DJ, Beedham C: Biotransformation of carbazeran in guinea pig: effect of hydralazine pretreatment. Xenobiotica 1994;24:37-47.
27. Wright RM, McManaman JL, Repine JE: Alcohol-induced breast cancer: a proposed mechanism. Free Rad Biol Med 1998;26:348-354.
28. Hochner-Celnikier D: Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Biol 1999;85:23-29.
29. Wolpert MK, Althaus JR, Johns DG: Nitroreductase activity of mammalian liver aldehyde oxidase. J Pharmacol Exp Ther 1973;185:202-213.